Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1995-06-23
1999-03-02
Wax, Robert A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
435236, 435238, 435 6, 4352351, 424 92, A12Q 170, A61K 4900, C12Q 168, C12N 704
Patent
active
058769200
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral protein.
BACKGROUND ART
It has been shown that certain membrane-associated proteins require the addition of lipophilic residues in order to function properly. One family of such modifications is termed "prenylation" because the hydrophobic residue is derived from isoprenoid precursors. The prenyl residue is known to attach to the sulfhydryl group of a cysteine which has been shown in a number of membrane-associated proteins to be contained in a "CXXX" (SEQ ID NO:1) box at the carboxy terminus of the substrate protein. In particular, one such membrane-associated protein has been shown to be the protein product of the ras oncogene. Summaries of these reactions conferring hydrophobic properties on membrane proteins, including prenylation, have appeared by Hoffman, M., Science (1991) 254:650-651, and by Gibbs, J. B., Cell (1991) 65:1-4.
In addition, in many cases, prenylation is a first step in a series of further reactions which modify the carboxy terminus of prenylated proteins. These prenylation initiated, or post-prenylation reactions include carboxymethylation and proteolysis.
In the prenylation substrate proteins studied to date, the CXXX (SEQ ID NO:1) box contains aliphatic residues in the second and third positions and a leucine, serine, methionine, cysteine or alanine in the terminal position. Thus, in the CXXX (SEQ ID NO:1) boxes so far studied, the box itself is relatively hydrophobic.
It has now been found that prenylation of a viral protein is necessary for the morphogenesis of hepatitis delta virus (HDV). This is the first demonstration that viral proteins are subject to prenylation. Furthermore, certain functional consequences can be ascribed to prenylation. The viral protein which is the target of prenylation, surprisingly, contains a hydrophilic CXXX (SEQ ID NO:1) box of the sequence Cys-Arg-Pro-Gln (SEQ ID NO:2). Prenylation, or prenylation-initiated modification, of this relatively hydrophilic CXXX (SEQ ID NO:1) box and corresponding CXXX (SEQ ID NO:1) boxes (hydrophilic or otherwise) or other cysteine-containing sequences near the C-terminus of proteins in other virions are suitable targets for antiviral strategies.
These targets can now be seen to include, but are not limited to, proteins of hepatitis A virus (HAV), hepatitis C virus (HCV), herpes simplex virus (HSV), cytomegalovirus (CMV), varicella-zoster virus (VZV), influenza virus, plant viruses such as tobacco mosaic satellite virus (TMSV) and barley stripe mosaic virus (BSMV), the core antigen of hepatitis B virus (HBV) and the nef gene product of human immunodeficiency virus-1 (HIV-1)--especially since nef has been shown to play an important role in the development of AIDS. (Kesstler, H. W. III, et al. Cell (1991) 65:651-662. Accordingly, inhibition of the prenylation of these target proteins or the post-prenylation reactions thereof is claimed to be inhibitory to the progress of these infections.
DISCLOSURE OF THE INVENTION
The invention provides methods to interfere with viral morphogenesis, production, release or uncoating both in vitro and in vivo. Agents which interfere with the prenylation of, or the post-prenylation reactions of, at least one viral protein are provided to infected cells to halt the viral infection. Such cells may be in culture or may be contained in an animal or plant subject.
Thus, in one aspect, the invention is directed to a method to inhibit viral morphogenesis, production, release or uncoating which method comprises effectively interfering with the prenylation of, or the post-prenylation reactions of, at least one viral protein. In another aspect, the invention is directed to an assay method for screening candidate drugs for their ability to inhibit prenylation. In a third aspect, the invention is directed to a method for treating viral infection by administering an agent effecti
REFERENCES:
patent: 5503973 (1996-04-01), Glenn
Finegold et al, Science 249:165-69, Jul. 13, 1990.
Schafer et al., Science 245: 379-85, Jul. 28, 1989.
Gibbs, Cell 65:1-4, Apr. 5, 1991.
Hancock et al, Cell 57:1167-1177, Jun. 30, 1989.
Hruby et al, Abs. of Am. Soc. for Microbio., 92nd Mtg.: 400, May 30, 1992.
Derwent Pub. Ltd., London.: Database WPI; Sec. Ch, Week 9430 (AN 94-247766).
Hoffman, M.; Playing Tag with Membrane Proteins; Science (1991) 254:650-651.
Kestler, H.W. III, et al.; Importance of the nef Gene for Maintenance of High Virus Loads and for Development of AIDS; Cell (1991) 65:651-662.
Overmayer et al. "Isoprenoid requirement for intracellular transport and processing of murine leukemia virus envelope protein", J. Biological Chemistry 267(31): 22686-22692, Nov. 5, 1992.
Miura et al. "Inhibition of protein prenylation by patulin", FEBS Letters 318(1):88-90, Feb. 1993.
Van Der Pyl et al. "Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin", J. Antibiotics 45(11):1802-1805, Nov. 1992.
Rightsel et al. "Antiviral activity of gliotoxin and gliotoxin acetate", Nature 204:1333-1334, Dec. 26, 1964.
Detroy et al. "Patulin inhibition of mycovirus replication in Penicillium stoloniferum", J. General Microbiology 92:167-174, 1975.
Ratner et al. "Nef". Current Topics Microbiol. Immunol. 193: 169-203, 1995.
Kaminchik et al. Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells. J. Virology 65(2):583-588, Feb. 1995.
Trono "HIV accessory proteins: leading roles for the supporting cast", Cell 82: 189-192, Jul. 28, 1995.
Bugaisky Gabriele E.
Wax Robert A.
LandOfFree
Methods for identifying anti viral agents and viruses that can b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying anti viral agents and viruses that can b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying anti viral agents and viruses that can b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-421267